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Abstract: PURPOSE The goal of this study was to objectively quantify cervical stiffness in misoprostol
users prior to IUC insertion and at follow-up consultation to evaluate the feasibility of assessing cervical
stiffness and to study the influence of misoprostol on cervical softening. MATERIALS AND METH-
ODS This was a cross-sectional study that evaluated 40 women who wished to use the LNG IUS. These
women were evaluated immediately before LNG IUS insertion and 6 weeks later at follow-up consulta-
tion. Participants received 200 ￿g of misoprostol combined with 75 mg of diclofenac in a single tablet
orally (Arthrotec forte 75/200(®), Pfizer, USA) 6-12 h prior to insertion in ”off label” use. On both oc-
casions, cervical stiffness was determined using a novel medical device based on the aspiration technique.
The Wilcoxon rank-sum and the Wilcoxon signed-rank test were applied to compare cervical stiffness
assessments at insertion of the IUD and at follow-up. RESULTS For the first time, cervical stiffness
was quantitatively assessed in misoprostol users prior to IUD insertion, proving that the aspiration tech-
nique enables detection of pharmacologically induced cervical changes, and also that misoprostol has a
detectable softening effect on cervical tissue. CONCLUSION The clinical value of the detected cervical
softening after misoprostol administration remains unclear. Aspiration measurements could be helpful in
searching for the ideal candidate, the appropriate route, dosage and interval of misoprostol intake prior
to IUC insertion.
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This study aims at the objective quantification of cervical stiffness in misoprostol 
users prior to IUC insertion and at follow up consultation to evaluate the feasibility of 
assessing cervical stiffness and to study the influence of misoprostol on cervical 
softening.  
Materials and Methods: This was a cross-sectional study that evaluated 40 women 
who wished to use the LNG IUS. These women were evaluated immediately before 
LNG IUS insertion and 6 weeks later at follow up consultation. Participants received 
200 μg of misoprostol combined with 75 mg of diclofenac in a single tablet orally 
(Arthrotec forte 75/200®, Pfizer, USA) 6 to 12 hours prior to insertion in “off label” 
use. On both occasions, cervical stiffness was determined using a novel medical 
device based on the aspiration technique. The Wilcoxon rank-sum and the Wilcoxon 
signed-rank test were applied to compare cervical stiffness assessments at insertion 
of the IUD and at follow up. 
Results: For the first time, cervical stiffness was quantitatively assessed in 
misoprostol users prior to IUD insertion, proving that the aspiration technique enables 
detection of pharmacologically induced cervical changes, and also that misoprostol 
has a detectable softening effect on cervical tissue.  
Conclusion: The clinical value of the detected cervical softening after misoprostol 
administration remains unclear. Aspiration measurements could be helpful in 
searching for the ideal candidate, the appropriate route, dosage and interval of 





Intrauterine contraceptives (IUC) belong to the most widely used family planning 
methods worldwide. Modern IUCs are reversible, long-acting, safe and cost-effective 
[1]. However, IUC uptake varies significantly across the world. Fear of pain during 
insertion is one of the well-known reasons that may prevent women from choosing an 
IUC as their method of choice [2,3]. For the vast majority, IUC insertion does not 
cause severe pain, but around 10 % of (multi-)para (P) [4] and 20 % of nulli-para (0P) 
[5] women report this procedure as very painful. It may, therefore, seem surprising 
that the need for pain relief during IUC insertion is still under debate and no generally 
accepted concept exists.  
Application of misoprostol, a prostaglandin analogue, activates inflammatory 
reactions [6,7] and induces microstructural changes in the cervical tissue leading to a 
disorganization of the collagenous network and thus cervical tissue softening 
(sometimes also called cervical ripening) [8,9].  
In OB/GYN, misoprostol has been widely administered in “off-label” usage to initiate 
the expected cervical softening as part of easing cervical dilation [4,10,11]. However, 
the cervical softening which is an indirect clinical feature and a requisite to facilitate 
cervical manipulations has so far never been quantified in-vivo.  
The never proven softening effect of misoprostol was also evaluated for pain 
reduction in IUC insertion [3], especially exploring the possible advantage for 0P, who 
generally present a narrow, stiff and un-stretched cervix [10,12,13] . Indeed, some 
studies found the use of misoprostol leads to an easier IUC passage through the 
cervical canal [14-16] and greater cervical dilation [15], but several other studies 
could not support the superiority of misoprostol administration, neither from the 
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doctor’s judgment regarding ease of insertion [4,17,18] nor from the patient’s 
judgment on lower pain perception [4,17]. In a large review, Gemzell-Danielsson et 
al. [19] found no conclusive evidence that prophylactic pharmacological interventions 
reduce pain on IUC insertion. This conflicting data, doubting the effectiveness of 
misoprostol, might arise from a lack of a standardized protocol for IUC insertion and 
drug application (route, time dosage) [19-22]. However, despite the lack of clear 
evidence of a beneficial effect of misoprostol, health care providers frequently 
recommend misoprostol administration in the belief that pain during IUC insertion is 
reduced [23].  
The state of scientific knowledge regarding the efficacy of different misoprostol 
regimen on cervical softening and on IUC insertion in general needs further research. 
The quantitative and objective assessment of cervical softening using a dedicated 
instrument is the first step towards an improved understanding. Such an instrument 
allows finding the optimal misoprostol treatment in terms of cervical softening which 
then can be further evaluated in terms of ease of insertion and its impact on pain 
management during IUC insertion. 
In the present study, we focused on acquiring objective data to measure the cervical 
stiffness using the aspiration method (ASP) [24]. Recently, the aspiration method has 
been tested successfully in a clinical study to describe cervical stiffness on 50 non-
pregnant and 50 pregnant subjects. For the first time the in-vivo measurements 
allowed us to quantify the continuous cervical softening during pregnancy [24,25]. To 
the best of our knowledge, aspiration is the only available and reliable method that 
allows us to objectively quantify the stiffness of the cervical tissue on humans in-vivo.  
This study aims at the objective quantification of cervical stiffness in misoprostol 
users prior to IUC insertion and at follow up consultation to evaluate the feasibility of 
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This cross-sectional study was approved by the IRB (KEK Zurich StV02/2007 and 
later amendments) and was conducted according to the Declaration of Helsinki. 
Subject informed consent was prerequisite for the study involvement. 
Participant selection 
From July 2013 all women presenting for IUC placement at our private office were 
invited to take part in the study. We focused on the 52 mg LNG IUS (LNG IUS, 
Mirena®, Bayer Healthcare, Germany), since in this unit more than 90% of the 
women chose an LNG IUS as their IUC. Non-inclusion criteria were communication 
problems, prior surgery on the cervix, untreated premalignant or malignant changes 
on the cervix, contraindications to using a LNG IUS, and the use of misoprostol or 
non-steroidal anti-inflammatory drugs. By October 2014, 40 women were included. 
Misoprostol and Diclofenac administration 
Participants received 200 μg of misoprostol combined with 75 mg of diclofenac in a 
single tablet orally (Arthrotec forte 75/200®, Pfizer, USA) 6 to 12 hours before 
insertion in “off label” use.  
Aspiration measurement 
Directly before LNG IUS insertion, aspiration measurements (Fig. 1) were performed, 
as previously described in detail [24,25] to measure cervical stiffness. To this end, 
the aspiration tube is placed orthogonally on the ecto-cervix at the 12 o’clock 
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position. Negative pressure (limited at maximum 500 mbar) on the cervical epithelium 
is applied to elevate the underlying tissue to a predefined level of deformation (4 
mm). The required pressure to deform the tissue (closure pressure: pcl) is registered. 
It is proportional to the stiffness of the cervical stroma [24,25] . 
Follow Up 
Aspiration measurements were repeated at regular follow up consultations including 
a sonographic IUC position check around 6 weeks after insertion.  
Study population 
40 Caucasians aged from 22 to 49 years of age (mean: 35 years), mostly parous 
subjects. 25 subjects underwent a first LNG IUS insertion, 15 subjects had a LNG 
IUS replacement. 
Statistics 
Statistical analysis was performed with the statistical computing environment R: A 
Language and Environment for Statistical Computing, Open Source Software, 2012. 
The Wilcoxon rank-sum test was used to compare differences between the 
previously investigated control group [24] and the two groups in this study, both prior 
to IUC placement (first insertion and replacement) and at follow up. For comparison 
of values of the same subjects at insertion and at follow up, the Wilcoxon signed-rank 





All new LNG IUS insertions as well as all replacements could be executed 
successfully. Immediate transvaginal ultrasound position check confirmed correct 
positioning in all cases, no perforation occurred. 
Aspiration measurements: 
Cervical stiffness (pcl) was successfully assessed in all subjects. The primary 
outcome was the pcl value (i.e. cervical stiffness) at insertion after misoprostol intake 
and at follow up without misoprostol. We found average values for pcl of 290 mbar +/- 
138 mbar (mean +/- SD) at insertion and 324 +/- 138 mbar at follow up showing no 
significant difference when assessing the group as a whole. However, when we 
divided the study population into first LNG IUS insertion and LNG IUS replacement, 
we found 230 mbar +/- 93 mbar (mean +/- SD) in the first LNG IUS insertion group (n 
= 25), and pcl of 396 mbar +/- 90 mbar in the LNG IUS replacement group (n = 15). 
The comparison with a historical control subjects (n = 50) published in Badir et al. 
[25] (320 mbar +/- 120 mbar) revealed that pcl at insertion was significantly lower (p = 
0.005) in the first LNG IUS insertions indicating a reduction in cervical stiffness. In 
contrast, the comparison between control subjects and LNG IUS replacement 
demonstrated a higher pcl in this group, but did not reach a statistical significance (p = 
0.08). Additionally, comparison of pcl values at insertion between first insertions and 
replacements showed a significant difference (p ≤ 0.001). Pre and post-comparison 
of pcl at insertion and at follow up demonstrated a differentiated behavior in cervical 
stiffness change in the two groups. In the first LNG IUS insertion group, cervical 
stiffness increased significantly (p ≤ 0.001) to a similar level (308 mbar +/- 105) at 
follow up as that expected from control group (320 mbar +/- 120 mbar) while in the 
LNG IUS replacement group cervical stiffness decreased significantly to the level of 
the control group (p = 0.03). See Fig. 2 for mean and standard deviation values, and 
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Fig. 3 for subject specific data. Closure pressure values obtained at follow up are not 
statistically different from the control group (first insertion, p = 0.6 and consecutive 
insertion, p = 0.7). The same non-significant finding is revealed in the comparison 
between pcl values between follow up after first LNG IUS placement and LNG IUS 
replacement (p = 0.5). 
Discussion 
For the first time, cervical stiffness was quantitatively assessed in misoprostol users 
prior to LNG IUS insertion, showing that i) ASP is able to detect pharmacologically 
induced cervical changes, and ii) misoprostol has a detectable softening effect on 
cervical tissue at first insertion.  
We compared measurements taken from women at their first LNG IUS insertion with 
their measurements taken around 6 weeks later (when there were no effects from the 
previous misoprostol administration). It was found that cervical stiffness was 
significantly lower initially with misoprostol but after 6 weeks cervical stiffness 
recovered to the reference stiffness values of non-pregnant women. 
In contrast, the group with an LNG IUS replacement did not show a decrease of 
cervical softening caused by misoprostol. Cervical stiffness was not significantly 
different, at insertion and at follow up some weeks later, and was comparable to the 
reference cohort. These results are in line with Heikinheimo et al., [4]. In their study 
misoprostol did not have an effect on the ease of insertion in subjects having a LNG 
IUS replacement.  
This surprise finding demands a further explanation. We can only assume that 
prostaglandin (misoprostol) induced cervical softening was blocked in the LNG IUS 
exchangers by the locally released LNG. This assumption is supported by the recent 
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literature. Murine infection-induced preterm birth models provided insight into the 
molecular and microstructural processes leading to cervical softening. Prostaglandins 
were found to be the promoter of these remodeling processes. Increased GAG 
synthesis induced by prostaglandins led to disintegration of the collagenous network 
thus leading to a detectable cervical softening. In these cases the softness of the 
cervical tissue was indistinguishable from that of cervices at term. Moreover using the 
same murine model, it was demonstrated that administration of progesterone 
inhibited prostaglandin induced cervical softening [6].  
In our study, 200 μg misoprostol and 75 mg diclofenac was given orally 6 - 12 hours 
prior to insertion of the LNG IUS. The oral administration route was chosen for 
practical reasons combined with a smaller dose of misoprostol, as discussed by Sääv 
et al. [14], to lower the incidence of uterine cramps. Nonetheless, diclofenac was co-
administered, as suggested by Gemzell-Danielsson et al. [19], to manage 
prostaglandin-induced side effects. In previous IUC insertion studies misoprostol was 
administered bucally [10], sublingually [14] or vaginally [15]. In contrast to our 
protocol the dosage of 400 μg administered in the above mentioned studies was 
significantly higher and the time lag between misoprostol intake and insertion was 
within 1 to 4 hours significantly shorter [4,10,17]. We decided for a longer priming 
interval based on the recommendations of different authors [11,14,21,22] critically 
addressed the importance of the time interval to induce significant cervical softening 
and to obtain the benefit of misoprostol for insertion. Since we measured a significant 
softening after misoprostol intake in the first LNG IUS insertions, our observation 
supports the importance of a priming interval of 6 to 12 hours. However, this study 
was not designed to answer this question.  
10 
 
The exact role of diclofenac remains unclear, but we believe that the very low rate of 
misoprostol induced uterine cramps (5%) in this study is the result of the diclofenac 
effect, as assumed in Bahamondes et al. [22].  
A limitation of this study is the lack of sub-analysis of the misoprostol effect on 0P 
versus P due to the small number of 0P subjects, and the restriction to only one 
typically used IUC. Another possible limitation to this study is that it was not 
conducted as a blind randomized controlled trial and cervical softening is an indirect 
clinical feature that does not allow to judge e.g. about ease of insertion, extent of 
cervical dilation or pain during IUC insertion. 
In summary, the aspiration method allowed simple and quantitative cervical stiffness 
assessment to evaluate the softening effect of misoprostol on the cervical tissue. Our 
results are indicative for misoprostol induced softening in subjects for first LNG IUS 
insertion. As a preliminary clinical consequence, based on our results, we could 
suggest a differentiated misoprostol administration policy, i.e. women undergoing first 
LNG IUS insertion might benefit from 200 μg oral misoprostol administration 6 - 12 
hours prior to insertion (evidence of cervical softening), whilst women undergoing 
LNG IUS replacement might not benefit from it (lack of cervical softening). However, 
cervical softening is an indirect clinical value and should be further studied by 
assessing clinical features such as ease of insertion or pain during insertion. Further 
aspiration measurements could be helpful in searching for the ideal candidate, the 
appropriate route, dosage and interval of misoprostol intake prior to IUC insertion. 
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Fig. 1 Aspiration device and measurement principle: (a) Trolley with the peristaltic 
pump, aspiration tube, pedals, and other technical equipment; (b) view of the 
cylindrical aspiration tube with the round contact-opening (diameter of 8 mm) at the 
tip is placed at 12 o’clock position on the cervix.; (c) inside of the aspirator head; (d) 
The pressure in the tube is reduced by extraction of air through the suction pipe. 
Cervical tissue is deformed into the aspiration tube until the tissue vault reaches and 
closes the suction pipe. The corresponding value of negative pressure is called 








Fig. 2: Results of closure pressure pcl (cervical stiffness) of the control group [25] and 
subjects at insertion and at follow up. Left: first LNG IUS insertions; Right: LNG IUS 
replacement. For all values, means and standard deviations and p-values are 




Figure 3: Pre and post-comparison of closure pressure pcl (cervical stiffness) of each 
subject individually at insertion and at follow up. Left: first LNG IUS insertion; Right: 
LNG IUS replacement. 
 
